 fluosol treatment sever anemia studi patient safeti efficaci fluosol fda blood substitut treatment sever anemia thirty-six patient fda starch ch part trial patient receiv fda part humanitarian protocol jehovah wit transfus averag hgb level g/dl pulmonari arteri cathet insert patient ch pulmonari arteri wedg pressur WP mm Hg fda one-tim dose ml/kg data baselin none patient neg reaction test dose fda advers reaction subsequ infus plasma compon oxygen content fda group fda group ml/dl control group ml/dl t-test nineteen patient fda control differ signific follow fda anem patient dose ml/kg fda dissolv compon oxygen content effect anem patient transfus mortal high studi inabl fda increas oxygen content due part rapid elimin fda limit amount